TOP > 外国特許検索 > HOST REGULATION FACTOR FOR ENHANCING PROLIFERATION AND PROPAGATION OF VACCINIA VIRUS

HOST REGULATION FACTOR FOR ENHANCING PROLIFERATION AND PROPAGATION OF VACCINIA VIRUS NEW

外国特許コード F170009025
整理番号 (S2015-1760-N0)
掲載日 2017年3月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP071538
国際公開番号 WO 2017014296
国際出願日 平成28年7月22日(2016.7.22)
国際公開日 平成29年1月26日(2017.1.26)
優先権データ
  • 特願2015-145153 (2015.7.22) JP
発明の名称 (英語) HOST REGULATION FACTOR FOR ENHANCING PROLIFERATION AND PROPAGATION OF VACCINIA VIRUS NEW
発明の概要(英語) The objective of the present invention is to provide a use for a UCA1 gene, which is a host regulation factor that enhances proliferation and propagation of the vaccinia virus, so that cancer virotherapy using the vaccinia virus can be effectively carried out. The present invention is: a method for making a predictive evaluation of the efficacy of a cancer treatment using the vaccinia virus, by measuring the expression of the UCA1 gene in cancer cells of a cancer patient, and if the UCA1 gene is expressed, predicting that a cancer treatment using the vaccinia virus will be effective in the patient; and a vaccinia virus introduced in a manner enabling UCA1 gene expression.
特許請求の範囲(英語) [claim1]
1. The method of measuring the revelation of the UCA1 gene in the cancer cell of the cancer patient, that when the UCA1 gene has revealed, there is cancer curative effect by the framework senior virus in the said patient estimating, it estimates appraising the cancer curative effect by the framework senior virus.
[claim2]
2. The framework senior virus, is the tumor dissolved framework senior virus, method of claim 1 statement.
[claim3]
3. In order the framework senior virus, for LC16 stocks, LC16mO stocks or the B5R gene to reveal, they are the LC16m8 stocks which are altered, in claim 1 or 2 method of statement.
[claim4]
4. Revelation of UCA1 heredity is measured due to RT-PCR, either of the claim 1-3 in 1 sections method of statement.
[claim5]
5. The UCA1 gene was introduced revelation possibly, the framework senior virus.
[claim6]
6. -cancer cell in with UCA1 gene reveal do, UCA1 control to depend cancer cell in with multiplication do, claim section 5 statement framework senior virus.
[claim7]
7. It is the tumor dissolved framework senior virus, in claim 5 or 6 the framework senior virus of statement.
[claim8]
8. In order the framework senior virus, for LC16 stocks, LC16mO stocks or the B5R gene to reveal, they are the LC16m8 stocks which are altered, either of the claim 5-7 in 1 sections the framework senior virus of statement.
[claim9]
9. Either of the claim 5-8 the medicine composition for the cancer remedy which includes the framework senior virus of statement in 1 sections.
[claim10]
10. It includes the UCA1 gene combining the manifestation vector and the framework senior virus which revelation possibly are introduced, the medicine composition kit for cancer remedy.
[claim11]
11. The framework senior virus, is the tumor dissolved framework senior virus, in claim 10 the medicine composition kit for cancer remedy of statement.
[claim12]
12. In order the framework senior virus, for LC16 stocks, LC16mO stocks or the B5R gene to reveal, they are the LC16m8 stocks which are altered, in claim 10 or 11 the medicine composition kit for cancer remedy of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOTTORI UNIVERSITY
  • 発明者(英語)
  • NAKAMURA TAKAFUMI
  • HORITA KOUSUKE
  • KUROSAKI HAJIME
  • NAKATAKE MOTOMU
国際特許分類(IPC)
指定国 (WO201714296)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close